Search hospitals > New Jersey > Berlin
Hassman Research Institute
Claim this profileBerlin, New Jersey 08009
Global Leader in Schizophrenia
Global Leader in Depression
Conducts research for Major Depressive Disorder
Conducts research for Opioid Use Disorder
Conducts research for Migraine
140 reported clinical trials
6 medical researchers
Summary
Hassman Research Institute is a medical facility located in Berlin, New Jersey. This center is recognized for care of Schizophrenia, Depression, Major Depressive Disorder, Opioid Use Disorder, Migraine and other specialties. Hassman Research Institute is involved with conducting 140 clinical trials across 112 conditions. There are 6 research doctors associated with this hospital, such as Michael Hassman, DO, Elan Cohen, PhD, Steven Glass, MD, and Steve Glass, MD.Area of expertise
1Schizophrenia
Global Leader2Depression
Global LeaderSelective Serotonin Reuptake Inhibitors (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
Top PIs
Michael Hassman, DOHassman Research Institute3 years of reported clinical research
Studies Diabetes
Studies Type 2 Diabetes
14 reported clinical trials
17 drugs studied
Elan Cohen, PhDHassman Research Institute2 years of reported clinical research
Studies Schizophrenia
Studies Depression
6 reported clinical trials
14 drugs studied
Steven Glass, MDHassman Research Institute3 years of reported clinical research
Studies Major Depressive Disorder
Studies Schizophrenia
4 reported clinical trials
7 drugs studied
Steve Glass, MDHassman Research Institute1 year of reported clinical research
Studies Pervasive Developmental Disorders
Studies Autism Spectrum Disorder
1 reported clinical trial
1 drug studied
Clinical Trials running at Hassman Research Institute
Obesity
Schizophrenia
Non-alcoholic Fatty Liver Disease
Attention Deficit Hyperactivity Disorder (ADHD)
Autism
Diabetes
Peanut Allergy
Type 2 Diabetes
Major Depressive Disorder
Obsessive-Compulsive Disorder
Tirzepatide
for Obesity
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Recruiting1 award Phase 39 criteria
PF-07081532 + Rybelsus
for Type 2 Diabetes and PF-07081532
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Rybelsus. Those in the obesity part of the study, will receive either active study drug or placebo. The study will last for about 36 weeks except for the first 25% of the participants that enter in which case the study will last for approximately 48 weeks. during this time there will be visits every 4 weeks with phone calls in between.
Recruiting0 awards Phase 24 criteria
Tirzepatide + Mibavademab
for Obesity
The main purpose of this study is to determine if combining tirzepatide with the mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 72 weeks and may include up to 19 visits.
Recruiting0 awards Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Hassman Research Institute?
Hassman Research Institute is a medical facility located in Berlin, New Jersey. This center is recognized for care of Schizophrenia, Depression, Major Depressive Disorder, Opioid Use Disorder, Migraine and other specialties. Hassman Research Institute is involved with conducting 140 clinical trials across 112 conditions. There are 6 research doctors associated with this hospital, such as Michael Hassman, DO, Elan Cohen, PhD, Steven Glass, MD, and Steve Glass, MD.